These findings suggest that a compromised ABCA1 pathway may contribute to increased atherogenesis in common inflammatory and metabolic disorders, making it a crucial target for potential cardiovascular disease therapies [215]. The gene discussed is ABCA1; the disease is cardiovascular disorder.